StockMacro
Menu

Abbvie

$286.20 +34% in 6 monthsMarket cap $505.9B

ABBV on XNYS, Health Care, ABBVIE INC., job postings

Measures activity, not value. Not investment advice.

Net income rose 333% to $10.3B over 12 months as revenue grew 11% to $66B.

  • GoodLatest quarter revenue rose 10% to $17.4B

Written by AI from the data on this page, 21 Nov 2026. Not investment advice.

Profile and fundamentals

From its SEC filings, 12 months to 30 Sep 2026

AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio, while the 2026 acquisition of Apogee adds to AbbVie's immunology depth.

Industry
Pharmaceutical preparations (Health Care)
Employees
57,000
Website
abbvie.com
Listed
NYSE, US
Last results
30 Oct 2026
Next results
expected around 6 Jan 2027 (an estimate: a year ago it reported on 7 Jan 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: revenue $17.4B, net income $4.2B.
Quarter to 31 Dec 2021: revenue $14.9B, net income $4.0BQuarter to 31 Dec 2021: revenue $14.9B, net income $4.0BQuarter to 31 Mar 2022: revenue $13.5B, net income $4.5BQuarter to 31 Mar 2022: revenue $13.5B, net income $4.5BQuarter to 30 Jun 2022: revenue $14.6B, net income $924.0MQuarter to 30 Jun 2022: revenue $14.6B, net income $924.0MQuarter to 30 Sep 2022: revenue $14.8B, net income $3.9BQuarter to 30 Sep 2022: revenue $14.8B, net income $3.9BQuarter to 31 Dec 2022: revenue $15.1B, net income $2.5BQuarter to 31 Dec 2022: revenue $15.1B, net income $2.5BQuarter to 31 Mar 2023: revenue $12.2B, net income $239.0MQuarter to 31 Mar 2023: revenue $12.2B, net income $239.0MQuarter to 30 Jun 2023: revenue $13.9B, net income $2.0BQuarter to 30 Jun 2023: revenue $13.9B, net income $2.0BQuarter to 30 Sep 2023: revenue $13.9B, net income $1.8BQuarter to 30 Sep 2023: revenue $13.9B, net income $1.8BQuarter to 31 Dec 2023: revenue $14.3B, net income $822.0MQuarter to 31 Dec 2023: revenue $14.3B, net income $822.0MQuarter to 31 Mar 2024: revenue $12.3B, net income $1.4BQuarter to 31 Mar 2024: revenue $12.3B, net income $1.4BQuarter to 30 Jun 2024: revenue $14.5B, net income $1.4BQuarter to 30 Jun 2024: revenue $14.5B, net income $1.4BQuarter to 30 Sep 2024: revenue $14.5B, net income $1.6BQuarter to 30 Sep 2024: revenue $14.5B, net income $1.6BQuarter to 31 Dec 2024: revenue $15.1B, net income -$22.0MQuarter to 31 Dec 2024: revenue $15.1B, net income -$22.0MQuarter to 31 Mar 2025: revenue $13.3B, net income $1.3BQuarter to 31 Mar 2025: revenue $13.3B, net income $1.3BQuarter to 30 Jun 2025: revenue $15.4B, net income $938.0MQuarter to 30 Jun 2025: revenue $15.4B, net income $938.0MQuarter to 30 Sep 2025: revenue $15.8B, net income $186.0MQuarter to 30 Sep 2025: revenue $15.8B, net income $186.0MQuarter to 31 Dec 2025: revenue $16.6B, net income $1.8BQuarter to 31 Dec 2025: revenue $16.6B, net income $1.8BQuarter to 31 Mar 2026: revenue $15.0B, net income $695.0MQuarter to 31 Mar 2026: revenue $15.0B, net income $695.0MQuarter to 30 Jun 2026: revenue $17.0B, net income $3.6BQuarter to 30 Jun 2026: revenue $17.0B, net income $3.6BQuarter to 30 Sep 2026: revenue $17.4B, net income $4.2BQuarter to 30 Sep 2026: revenue $17.4B, net income $4.2B
31 Dec 2021RevenueNet incomeNet losstallest bar $17.4B30 Sep 2026
See the numbers
Quarter toRevenueNet income
30 Sep 2026$17.4B$4.2B
30 Jun 2026$17.0B$3.6B
31 Mar 2026$15.0B$695.0M
31 Dec 2025$16.6B$1.8B
30 Sep 2025$15.8B$186.0M
30 Jun 2025$15.4B$938.0M
31 Mar 2025$13.3B$1.3B
31 Dec 2024$15.1B-$22.0M
30 Sep 2024$14.5B$1.6B
30 Jun 2024$14.5B$1.4B
31 Mar 2024$12.3B$1.4B
31 Dec 2023$14.3B$822.0M
30 Sep 2023$13.9B$1.8B
30 Jun 2023$13.9B$2.0B
31 Mar 2023$12.2B$239.0M
31 Dec 2022$15.1B$2.5B
30 Sep 2022$14.8B$3.9B
30 Jun 2022$14.6B$924.0M
31 Mar 2022$13.5B$4.5B
31 Dec 2021$14.9B$4.0B
Fundamentals, 12 months to 30 Sep 2026
MeasureLatestYear beforePeer median
RevenueSales over the last 12 months reported. $66.0B $59.6B
Revenue growthRevenue of the last 12 months compared with the 12 months before. +11% +11%
Net incomeProfit after all costs and taxes over the last 12 months reported. Negative is a loss. $10.3B $2.4B
EPS (diluted)Earnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split). $5.81 $1.32
Gross marginWhat is left of each dollar of sales after the direct cost of making the product or service. 73.7% 69.7% 73.2%
Operating marginOperating income as a share of sales: profit from the business before interest and taxes. 32.2% 15.2% -25.0%
Net marginNet income as a share of sales: what the owners keep of each dollar sold. 15.7% 4.0% -18.2%
Return on equityNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money. – -58.8%
Free cash flowCash from operations minus capital spending over the last 12 months: cash the business produced. $18.9B $19.7B
CashCash, cash equivalents and short-term investments on the latest balance sheet. $10.8B $5.7B
DebtShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted. $80.9B $68.7B
Net debtDebt minus cash. Negative means the company holds more cash than it owes (net cash). $70.1B $63.1B
Debt to equityDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative. – 0.0
Book value per shareShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding. –
P/EPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss. 48.9 19.3
P/SPrice to sales: market cap divided by revenue of the last 12 months. 7.7 5.0
EV/SalesEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months. 8.7 5.0
P/BPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative. – 2.0
Dividend yieldDividends per share declared in the latest fiscal year divided by the share price. 2.3% 2.5%

Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.

Peers nearest by market cap, its own industry first

CompanyMarket capP/EP/SRevenue growthNet margin
AbbvieABBV (this company) $505.9B48.97.7+11%15.7%
Johnson & JohnsonJNJ $651.1B40.56.6+7.8%16.2%
MerckMRK $329.7B1344.9+4.9%3.6%
Eli LillyLLY $1.2T45.914.7+46%31.9%
Abbott LaboratoriesABT $178.4B37.93.7+10%9.7%
PfizerPFE $156.2B38.72.5+1.3%6.3%

Insider Buy/Sell Shares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.

-$11.9M

bought $0, sold $11.9M

Institutional holders The number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.

+2.3%

4,229 13F filers vs 4,132

Institutional ownership Shares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.

74%

1.3B shares held by 13F filers (30 Sep 2026) of 1.8B outstanding (26 Oct 2026)

Short interest Shares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.

0.9%

15.8M shares sold short (30 Oct 2026) of 1.8B outstanding (26 Oct 2026)

Days to cover Short interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.

3.3

15.8M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it

Short interest change How the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.

+1.5%

15.6M shares sold short in the report before, 15.8M on 30 Oct 2026

Short sale volume Share of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.

34%

34% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 46%

Open jobs Job postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.

–

We do not track this company's careers site yet.

Open jobs change How the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.

–

We do not track this company's careers site yet.

Employees Total staff the company reported in its latest annual report (10-K), with the change from the year before when both years are reported.

–

No headcount in its annual reports in our data.

Visa hiring (foreign workers) Applications to hire foreign specialists on H-1B and E-3 visas certified by the Labor Department in the last 12 months, compared with the 12 months before. This is NOT total hiring: most hires need no visa. Open jobs shows total hiring where we track it.

-23%

210 vs 271 applications

Revenue growth Sales in the latest reported quarter compared with the same quarter a year earlier.

+10%

$17.4B vs $15.8B (quarter ended 30 Sep 2026)

Capital spending Money spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.

-21%

$301.0M vs $381.0M (quarter ended 30 Sep 2026)

Federal contracts Money the US government committed to the company in contracts and grants over the last 12 months.

–

No data for this company

Lobbying What the company reported spending on federal lobbying over the last four quarters.

$5.6M

4 quarters, $

Layoff notices Workers named in state WARN layoff notices over the last 12 months (employers must file them 60 days before a large layoff).

–

No data for this company

News (7d) Articles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.

56

56 articles in the last 7 days; its usual week has 9.5 (the median of the 26 weeks before).

News vs usual Articles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.

5.9×

56 articles in the last 7 days; its usual week has 9.5.

Price $286.20 on 20 Nov 2026, +25% over 12 months (12-month range $197.38 to $295.03)

  • Sharp change
  • 8-K and other filings
  • Lobbying filing
Insider net buying (open market). Insiders sold a net $30.8M in the last 12 months (the 12 months before: -$69.1M).
H-1B/E-3 applications certified. H-1B/E-3 applications certified: 208 published in the last 12 months, -24% on the 12 months before.
Revenue per quarter. Revenue $17.4B in the latest quarter, +10% on a year earlier.
Capital spending per quarter. Capital spending $301.0M in the latest quarter, -21% on a year earlier.
Institutional holders (13F filers). 4,229 13F filers reported holding it in the latest 13F quarter, +14% on a year earlier.
Federal obligations. Federal obligations: -$2.3M published in the last 12 months, -473% on the 12 months before.
Lobbying spend. Lobbying spend: $5.6M published in the last 12 months, +5.8% on the 12 months before.

Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: workers in warn layoff notices.

See the numbers
Dated facts on the price chart (newest 100)
Became publicKindFact
2 Nov 20268-K and other filingsDirector or officer change
20 Oct 2026Lobbying filingnew lobbying registration (B HALL STRATEGIES, LLC)
15 Oct 20268-K and other filingsDirector or officer change
15 Oct 2026Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
21 Apr 2026Sharp changeLobbying on a new issue: lobbying on a new issue: CSP (2026-03-31)
7 Apr 2026Sharp changeWikipedia attention spike: wikipedia attention spike, 7,134 vs usual 3,559 (2026-03-30..2026-04-05); 1.8x the same week a year earlier
20 Mar 2026Lobbying filingnew lobbying registration (WILLIAMS AND JENSEN, PLLC)
11 Feb 2026Lobbying filingnew lobbying registration (CHECKMATE GOVERNMENT RELATIONS)
18 Nov 2025Sharp changeMany funds opening a new position: many funds opening a new position, 228 vs usual 117.50 (2025-09-30); 1.3x the same period a year earlier
6 Nov 2025Sharp changeQuarterly capital spending jump: quarterly capital spending jump, 381.0M vs usual 238.0M (2025-09-30); 1.5x the same period a year earlier
22 Jul 2025Sharp changeLobbying on a new issue: lobbying on a new issue: TAR (2025-06-30)
21 Jul 2025Lobbying filingnew lobbying registration (ACG ADVOCACY)
15 May 2025Sharp changeMany funds opening a new position: many funds opening a new position, 196 vs usual 108.50 (2025-03-31); 1.4x the same period a year earlier
12 May 20258-K and other filingsDirector or officer change
14 Feb 20258-K and other filingsDirector or officer change
10 Jan 20258-K and other filingsAsset write-down (impairment)
13 Dec 20248-K and other filingsDirector or officer change
13 Dec 2024Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
17 Sep 2024Sharp changeH-1B/E-3 applications change: h-1B/E-3 applications change, 45 vs usual 15 in the same month of earlier years (2024-05-01..2024-05-31); 3.2x the same month a year earlier
27 Aug 2024Sharp changeShort interest spike: short interest spike, 20.2M vs usual 13.6M (2024-08-15); 1.5x the same period a year earlier
23 Apr 2024Sharp changeLobbying on a new issue: lobbying on a new issue: LBR (2024-03-31)
20 Feb 20248-K and other filingsDirector or officer change
20 Feb 2024Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
12 Oct 20238-K and other filingsDirector or officer change
12 Oct 2023Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
11 Sep 2023Lobbying filingnew lobbying registration (MARSHALL & POPP, LLC)
29 Jun 20238-K and other filingsDirector or officer change
29 Jun 2023Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
31 Jan 2023Sharp changeWikipedia attention spike: wikipedia attention spike, 5,621 vs usual 3,344 (2023-01-23..2023-01-29); 1.5x the same week a year earlier
20 Jan 2023Lobbying filinglobbying engagement terminated (OGR)
29 Nov 20228-K and other filingsDirector or officer change
17 Oct 20228-K and other filingsDirector or officer change
14 Oct 20228-K and other filingsDirector or officer change
14 Oct 2022Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
4 Oct 2022Sharp changeH-1B/E-3 applications change: h-1B/E-3 applications change, 57 vs usual 15 in the same month of earlier years (2022-05-01..2022-05-31); 3.6x the same month a year earlier
28 Jun 20228-K and other filingsDirector or officer change
13 Apr 20228-K and other filingsDirector or officer change
4 Mar 20228-K and other filingsDirector or officer change
17 Dec 20218-K and other filingsDirector or officer change
16 Dec 20218-K and other filingsDirector or officer change
16 Dec 2021Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
Insider net buying (open market)
Month from 1 Dec 2021: -$53.8M published
Month from 1 Feb 2022: -$338K published
Month from 1 Mar 2022: -$27.6M published
Month from 1 May 2022: -$101.2M published
Month from 1 Dec 2022: -$6.9M published
Month from 1 Feb 2023: -$13.0M published
Month from 1 Mar 2023: -$27.2M published
Month from 1 Apr 2023: -$5.2M published
Month from 1 Aug 2023: -$11.7M published
Month from 1 Dec 2023: -$451K published
Month from 1 Feb 2024: -$11.6M published
Month from 1 Mar 2024: -$69.6M published
Month from 1 Jul 2024: -$49.5M published
Month from 1 Aug 2024: -$12.4M published
Month from 1 Dec 2024: -$310K published
Month from 1 Feb 2025: -$1.1M published
Month from 1 Mar 2025: -$44.2M published
Month from 1 Apr 2025: -$12.4M published
Month from 1 Aug 2025: -$11.0M published
Month from 1 Feb 2026: -$5.1M published
Month from 1 Mar 2026: -$5.6M published
Month from 1 Aug 2026: -$8.2M published
Month from 1 Nov 2026: -$11.9M published
H-1B/E-3 applications certified
Quarter from 1 Jan 2022: 33 published
Quarter from 1 Apr 2022: 85 published
Quarter from 1 Jul 2022: 94 published
Quarter from 1 Oct 2022: 60 published
Quarter from 1 Jan 2023: 43 published
Quarter from 1 Apr 2023: 64 published
Quarter from 1 Jul 2023: 71 published
Quarter from 1 Oct 2023: 40 published
Quarter from 1 Jan 2024: 24 published
Quarter from 1 Apr 2024: 42 published
Quarter from 1 Jul 2024: 73 published
Quarter from 1 Oct 2024: 41 published
Quarter from 1 Jan 2025: 68 published
Quarter from 1 Apr 2025: 47 published
Quarter from 1 Jul 2025: 100 published
Quarter from 1 Oct 2025: 58 published
Quarter from 1 Jan 2026: 44 published
Quarter from 1 Apr 2026: 39 published
Quarter from 1 Jul 2026: 94 published
Quarter from 1 Oct 2026: 31 published
Revenue per quarter
Quarter ended 31 Dec 2021: $14.9B, +7.4% on a year earlier; public on 19 Feb 2022
Quarter ended 31 Mar 2022: $13.5B, +4.1% on a year earlier; public on 7 May 2022
Quarter ended 30 Jun 2022: $14.6B, +4.5% on a year earlier; public on 5 Aug 2022
Quarter ended 30 Sep 2022: $14.8B, +3.3% on a year earlier; public on 5 Nov 2022
Quarter ended 31 Dec 2022: $15.1B, +1.6% on a year earlier; public on 18 Feb 2023
Quarter ended 31 Mar 2023: $12.2B, -9.7% on a year earlier; public on 6 May 2023
Quarter ended 30 Jun 2023: $13.9B, -4.9% on a year earlier; public on 8 Aug 2023
Quarter ended 30 Sep 2023: $13.9B, -6.0% on a year earlier; public on 7 Nov 2023
Quarter ended 31 Dec 2023: $14.3B, -5.4% on a year earlier; public on 21 Feb 2024
Quarter ended 31 Mar 2024: $12.3B, +0.7% on a year earlier; public on 4 May 2024
Quarter ended 30 Jun 2024: $14.5B, +4.3% on a year earlier; public on 8 Aug 2024
Quarter ended 30 Sep 2024: $14.5B, +3.8% on a year earlier; public on 5 Nov 2024
Quarter ended 31 Dec 2024: $15.1B, +5.6% on a year earlier; public on 15 Feb 2025
Quarter ended 31 Mar 2025: $13.3B, +8.4% on a year earlier; public on 10 May 2025
Quarter ended 30 Jun 2025: $15.4B, +6.6% on a year earlier; public on 5 Aug 2025
Quarter ended 30 Sep 2025: $15.8B, +9.1% on a year earlier; public on 5 Nov 2025
Quarter ended 31 Dec 2025: $16.6B, +10% on a year earlier; public on 21 Feb 2026
Quarter ended 31 Mar 2026: $15.0B, +12% on a year earlier; public on 9 May 2026
Quarter ended 30 Jun 2026: $17.0B, +10% on a year earlier; public on 4 Aug 2026
Quarter ended 30 Sep 2026: $17.4B, +10% on a year earlier; public on 4 Nov 2026
Capital spending per quarter
Quarter ended 31 Dec 2021: $187.0M, -33% on a year earlier; public on 19 Feb 2022
Quarter ended 31 Mar 2022: $162.0M, -14% on a year earlier; public on 7 May 2022
Quarter ended 30 Jun 2022: $143.0M, -27% on a year earlier; public on 5 Aug 2022
Quarter ended 30 Sep 2022: $177.0M, -18% on a year earlier; public on 5 Nov 2022
Quarter ended 31 Dec 2022: $213.0M, +14% on a year earlier; public on 18 Feb 2023
Quarter ended 31 Mar 2023: $175.0M, +8.0% on a year earlier; public on 6 May 2023
Quarter ended 30 Jun 2023: $178.0M, +24% on a year earlier; public on 8 Aug 2023
Quarter ended 30 Sep 2023: $219.0M, +24% on a year earlier; public on 7 Nov 2023
Quarter ended 31 Dec 2023: $205.0M, -3.8% on a year earlier; public on 21 Feb 2024
Quarter ended 31 Mar 2024: $193.0M, +10% on a year earlier; public on 4 May 2024
Quarter ended 30 Jun 2024: $241.0M, +35% on a year earlier; public on 8 Aug 2024
Quarter ended 30 Sep 2024: $249.0M, +14% on a year earlier; public on 5 Nov 2024
Quarter ended 31 Dec 2024: $291.0M, +42% on a year earlier; public on 15 Feb 2025
Quarter ended 31 Mar 2025: $235.0M, +22% on a year earlier; public on 10 May 2025
Quarter ended 30 Jun 2025: $269.0M, +12% on a year earlier; public on 5 Aug 2025
Quarter ended 30 Sep 2025: $381.0M, +53% on a year earlier; public on 5 Nov 2025
Quarter ended 31 Dec 2025: $329.0M, +13% on a year earlier; public on 21 Feb 2026
Quarter ended 31 Mar 2026: $265.0M, +13% on a year earlier; public on 9 May 2026
Quarter ended 30 Jun 2026: $322.0M, +20% on a year earlier; public on 4 Aug 2026
Quarter ended 30 Sep 2026: $301.0M, -21% on a year earlier; public on 4 Nov 2026
Institutional holders (13F filers)
31 Dec 2021 report: 2,623; public on 14 Feb 2022
31 Mar 2022 report: 2,838; public on 16 May 2022
30 Jun 2022 report: 2,820; public on 15 Aug 2022
30 Sep 2022 report: 2,726; public on 14 Nov 2022
31 Dec 2022 report: 2,874; public on 14 Feb 2023
31 Mar 2023 report: 2,920; public on 15 May 2023
30 Jun 2023 report: 2,814; public on 14 Aug 2023
30 Sep 2023 report: 2,865; public on 14 Nov 2023
31 Dec 2023 report: 3,050; public on 14 Feb 2024
31 Mar 2024 report: 3,159; public on 15 May 2024
30 Jun 2024 report: 3,166; public on 14 Aug 2024
30 Sep 2024 report: 3,294; public on 14 Nov 2024
31 Dec 2024 report: 3,483; public on 14 Feb 2025
31 Mar 2025 report: 3,626; public on 15 May 2025
30 Jun 2025 report: 3,583; public on 14 Aug 2025
30 Sep 2025 report: 3,711; public on 14 Nov 2025
31 Dec 2025 report: 3,930; public on 17 Feb 2026
31 Mar 2026 report: 3,962; public on 15 May 2026
30 Jun 2026 report: 4,132; public on 14 Aug 2026
30 Sep 2026 report: 4,229; public on 16 Nov 2026
Federal obligations
Month from 1 Sep 2022: $14K published
Month from 1 Oct 2022: $15K published
Month from 1 Nov 2022: $3K published
Month from 1 Jan 2023: $41K published
Month from 1 Mar 2023: -$7K published
Month from 1 Apr 2023: $4K published
Month from 1 May 2023: $30K published
Month from 1 Jun 2023: $48K published
Month from 1 Jul 2023: $18K published
Month from 1 Aug 2023: $51K published
Month from 1 Sep 2023: $18K published
Month from 1 Oct 2023: $32K published
Month from 1 Nov 2023: $622 published
Month from 1 Dec 2023: $57K published
Month from 1 Jan 2024: $30K published
Month from 1 Feb 2024: $45K published
Month from 1 Mar 2024: $62K published
Month from 1 Apr 2024: $35K published
Month from 1 May 2024: $63K published
Month from 1 Jun 2024: $93K published
Month from 1 Jul 2024: $106K published
Month from 1 Aug 2024: $96K published
Month from 1 Sep 2024: $40K published
Month from 1 Oct 2024: $10K published
Month from 1 Nov 2024: $46K published
Month from 1 Dec 2024: $67K published
Month from 1 Jan 2025: $6K published
Month from 1 Feb 2025: $73K published
Month from 1 Mar 2025: $59K published
Month from 1 Apr 2025: $30K published
Month from 1 May 2025: $104K published
Month from 1 Jun 2025: $21K published
Month from 1 Jul 2025: $87K published
Month from 1 Aug 2025: $18K published
Month from 1 Sep 2025: $51K published
Month from 1 Oct 2025: $56K published
Month from 1 Nov 2025: $34K published
Month from 1 Dec 2025: -$2.7M published
Month from 1 Jan 2026: $23K published
Month from 1 Feb 2026: $31K published
Month from 1 Mar 2026: $58K published
Month from 1 Apr 2026: $56K published
Month from 1 May 2026: $62K published
Month from 1 Jun 2026: $44K published
Month from 1 Jul 2026: $34K published
Month from 1 Aug 2026: $34K published
Month from 1 Sep 2026: $21K published
Month from 1 Oct 2026: $24K published
Lobbying spend
Quarter from 1 Jan 2022: $1.3M published
Quarter from 1 Apr 2022: $4.0M published
Quarter from 1 Jul 2022: $880K published
Quarter from 1 Oct 2022: $2.4M published
Quarter from 1 Jan 2023: $970K published
Quarter from 1 Apr 2023: $1.5M published
Quarter from 1 Jul 2023: $600K published
Quarter from 1 Oct 2023: $750K published
Quarter from 1 Jan 2024: $830K published
Quarter from 1 Apr 2024: $1.6M published
Quarter from 1 Jul 2024: $580K published
Quarter from 1 Oct 2024: $1.3M published
Quarter from 1 Jan 2025: $1.1M published
Quarter from 1 Apr 2025: $2.1M published
Quarter from 1 Jul 2025: $1.2M published
Quarter from 1 Oct 2025: $980K published
Quarter from 1 Jan 2026: $1.3M published
Quarter from 1 Apr 2026: $2.1M published
Quarter from 1 Jul 2026: $1.2M published
Quarter from 1 Oct 2026: $1.1M published

What is unusual now

  • Nothing unusual in the last 90 days: no change appeared. Its most unusual measure now is workers named in WARN notices at 26 (28 Jun 2021), 68% below its normal reading of 81.5.
  • Insider net buying (open market): Insiders sold a net $30.8M in the last 12 months (the 12 months before: -$69.1M).
  • H-1B/E-3 applications certified: H-1B/E-3 applications certified: 208 published in the last 12 months, -24% on the 12 months before.
  • Revenue per quarter: Revenue $17.4B in the latest quarter, +10% on a year earlier.

Latest records

The names and amounts behind the totals, newest first

Last 90 days: 1 sale, $11.9M; no purchases. Open-market trades by officers, directors and 10% owners.

FiledInsiderTradeSharesPriceValueSource
12 Nov 2026Jeffrey Ryan StewartEVP, CHIEF COMMERCIAL OFFICERSellafter exercising options40,619$293.60$11.9MForm 4
18 Aug 2026Nicholas DonoghoeEVP, CHIEF BUS/STRAT OFFICERSellafter exercising options32,710$250.00$8.2MForm 4
6 Mar 2026David Ryan PurdueSVP, ControllerSell5,230$233.56$1.2MForm 4
3 Mar 2026Perry C SiatisEVP, GC AND SECRETARYSellplanned in advance (10b5-1)18,668$234.39$4.4MForm 4
27 Feb 2026Perry C SiatisEVP, GC AND SECRETARYSellplanned in advance (10b5-1); after exercising options22,381$230.00$5.1MForm 4
14 Aug 2025Azita Saleki-GerhardtEVP, CHIEF OPERATIONS OFFICERSellafter exercising options42,370$198.42$8.4MForm 4
7 Aug 2025Nicholas DonoghoeEVP, CHIEF BUS/STRAT OFFICERSell13,295$198.51$2.6MForm 4
2 Apr 2025Jeffrey Ryan StewartEVP, CHIEF COMMERCIAL OFFICERSellafter exercising options58,832$210.08$12.4MForm 4

4,229 institutions reported shares at the end of Q3 2026, 74% of the shares outstanding; 162 opened a position, 92 sold out. From 13F reports.

InstitutionShares% of companyValueChange vs Q2 2026
BlackRock, Inc.149.0M8.43%$39.0B-513K-0.3%
Vanguard Capital Management LLC115.7M6.54%$30.3B+281K+0.2%
State Street Corp82.8M4.69%$21.7B+219K+0.3%
Vanguard Portfolio Management LLC49.0M2.77%$12.8B+523K+1.1%
Geode Capital Management, LLC47.5M2.69%$12.4B+505K+1.1%
JPMorgan Chase & Co45.3M2.56%$11.9B-2.5M-5.3%
Morgan Stanley38.4M2.17%$10.0B-502K-1.3%
Capital Research Global Investors31.1M1.76%$8.1B+1.0M+3.4%
Bank of America Corp26.4M1.49%$6.9B+5.1M+24%
Capital World Investors20.7M1.17%$5.4B+1.5M+7.7%

Company events

All 47 company events

In 12 months: 2 director or officer changes. Results releases and routine reports are left out.

FiledWhat happenedSource
2 Nov 2026Director or officer change8-K
15 Oct 2026Director or officer change8-K
12 May 2025Director or officer changeSame filing: shareholder vote results8-K
14 Feb 2025Director or officer change8-K
10 Jan 2025Asset write-down (impairment)8-K
13 Dec 2024Director or officer change8-K
20 Feb 2024Director or officer change8-K
12 Oct 2023Director or officer change8-K

Reported lobbying spend: $1.1M in Q3 2026, $1.2M in Q2 2026. Rows are lobbying firms hired or let go; amounts are reported per quarter, not per firm here.

DateChangeLobbying firmIssueSource
1 Sep 2026NewB Hall Strategies, LLCfor Tiber Creek Group Obo Abbvie Inc.Issues related to reimbursement of medications under Medicare Part B.Medicare/MedicaidFiling
20 Mar 2026NewWilliams And Jensen, PLLCfor Abbvie, Inc.Providing strategic counsel on congressional and administrative issues, including drug pricing, Medicare and Medicaid, 340B, tax and trade, intellectual property, and FDA regulatory matters.PharmacyFiling
21 Jan 2026NewCheckmate Government Relationsfor Abbvie Inc.Issues regarding life sciences related matters.Health issues, Medicare/MedicaidFiling
1 May 2025NewAcg Advocacyfor AbbvieTrade Policy.TradeFiling
6 Sep 2023NewMarshall & Popp, LLCfor Abbvie Inc.Issues related to federal healthcare policy.Pharmacy, Health issuesFiling
31 Dec 2022EndedOgrfor Abbvie Inc.Policy proposals relating to economic activity in Puerto Rico; implementation of H.R.5376, Inflation Reduction Act of 2022 (P.L.117-169).; Discussions related to health care reform, access to health care, drug pricing, PDUFA Reauthorization, and international access to medicines; Implementation of H.R.5376, Inflation Reduction Act of 2022 (P.L.117-169); H.R.5801, HELP Copays Act; H.R.7667, Food and Drug Amendments of 2022; S.4348, FDASTaxation, Health issuesFiling
16 Apr 2021NewCornerstone Government Affairs, Inc.for Abbvie Inc.International tax issues and pharmaceutical pricing issues.Taxation, Health issuesFiling
2 Apr 2021NewOgrfor Abbvie Inc.Advocacy related to health care reform, access to health care, Medicare and Medicaid issues.Health issues, Medicare/MedicaidFiling

Layoff notices

All 4 layoff notices

No notice in 12 months; the latest is dated 1 Jul 2021. State WARN notices.

NoticeSiteWorkersJobs endSource
1 Jul 2021AbbVie IncMadison, NJ108 Oct 2021Notice
1 Jul 2021AbbVie IncNorth Brunswick, NJ168 Oct 2021Notice
21 Dec 2015AbbVie, Inc.Lake County, IL671 Jan 2016closureNotice
30 May 2012AbbVie, Inc.Lake County, IL961 Jun 2013closureNotice

The 5 newest of 964 articles that name the company.

Timeline

Several things at once

Two or more unrelated kinds of records unusual within 30 days

21 Apr 2026confirmed

Confirmed across sources Attention and Lobbying

Abbvie (ABBV): drew 7,134 Wikipedia page views in the week of 30 Mar 2026, 1.8× the same week last year, while it lobbying on a new issue. Two unrelated kinds of activity within 13 days.

  • Attention: Wikipedia attention spike, became public on 7 Apr 2026
  • Lobbying: Lobbying on a new issue, became public on 21 Apr 2026
2025-09-29: 4,4652025-10-06: 3,7172025-10-13: 3,4882025-10-20: 3,3742025-10-27: 3,4562025-11-03: 3,3582025-11-10: 3,5672025-11-17: 3,6032025-11-24: 3,5292025-12-01: 3,7722025-12-08: 3,6482025-12-15: 3,6682025-12-22: 2,5112025-12-29: 2,5422026-01-05: 3,8892026-01-12: 4,3412026-01-19: 4,1022026-01-26: 4,1732026-02-02: 4,1902026-02-09: 3,5022026-02-16: 3,3522026-02-23: 3,5812026-03-02: 3,3142026-03-09: 3,2742026-03-16: 3,4462026-03-23: 3,5512026-03-30: 7,134
The week of 30 Mar 2026 against the 26 weeks before it. this weekearliernormal: 3,559
See the evidence (2 changes)

Attention: Wikipedia attention spike became public on 7 Apr 2026

Abbvie drew 7,134 Wikipedia page views in the week of 30 Mar 2026, 1.8× the same week last year.

This period
7,134 (the week of 30 Mar 2026)
Normal week (median of 26 earlier)
3,559
Typical spread (median absolute deviation)
193
How far from its usual level
+10.0
Same week last year
3,941
History used
2,651 days
2025-09-29: 4,4652025-10-06: 3,7172025-10-13: 3,4882025-10-20: 3,3742025-10-27: 3,4562025-11-03: 3,3582025-11-10: 3,5672025-11-17: 3,6032025-11-24: 3,5292025-12-01: 3,7722025-12-08: 3,6482025-12-15: 3,6682025-12-22: 2,5112025-12-29: 2,5422026-01-05: 3,8892026-01-12: 4,3412026-01-19: 4,1022026-01-26: 4,1732026-02-02: 4,1902026-02-09: 3,5022026-02-16: 3,3522026-02-23: 3,5812026-03-02: 3,3142026-03-09: 3,2742026-03-16: 3,4462026-03-23: 3,5512026-03-30: 7,134
the week of 30 Mar 202626 earlier weeksnormal: 3,559

Fires when the period is at least 5.0 robust standard deviations above the company's own median, with 20+ earlier periods, 365+ days of history and a value of at least 5,000.

Check it at the source: Wikimedia page view statistics.

Lobbying: Lobbying on a new issue became public on 21 Apr 2026

Abbvie lobbying on a new issue.

New
['CSP']
Rule
only points whose every posting (and value revision) is at or before as_of
Field
issue_codes
Metric
lobbying.filings_count
Point id
4685366

Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

18 Nov 2025confirmed

Confirmed across sources Institutional holdings and Filings + Financials

Abbvie (ABBV): spent $381.0M on capital projects in the quarter ended 30 Sep 2025, 1.5× the same quarter last year, while it saw 228 13F filers open a new position in the quarter ended 30 Sep 2025, 1.3× the same quarter last year. Two unrelated kinds of activity within 12 days.

  • Financials: Quarterly capital spending jump, became public on 6 Nov 2025
  • Institutional holdings: Many funds opening a new position, became public on 14 Nov 2025
2023-09-30: $219.0M2023-12-31: $205.0M2024-03-31: $193.0M2024-06-30: $241.0M2024-09-30: $249.0M2024-12-31: $291.0M2025-03-31: $235.0M2025-06-30: $269.0M2025-09-30: $381.0M
The quarter ended 30 Sep 2025 against the 8 quarters before it. this quarterearliernormal: $238.0M
See the evidence (2 changes)

Financials: Quarterly capital spending jump became public on 6 Nov 2025

Abbvie spent $381.0M on capital projects in the quarter ended 30 Sep 2025, 1.5× the same quarter last year.

This period
$381.0M (the quarter ended 30 Sep 2025)
Normal quarter (median of 8 earlier)
$238.0M
Typical spread (median absolute deviation)
$25.0M
How far from its usual level
+3.9
Same quarter last year
$249.0M
History used
3,470 days
2023-09-30: $219.0M2023-12-31: $205.0M2024-03-31: $193.0M2024-06-30: $241.0M2024-09-30: $249.0M2024-12-31: $291.0M2025-03-31: $235.0M2025-06-30: $269.0M2025-09-30: $381.0M
the quarter ended 30 Sep 20258 earlier quartersnormal: $238.0M

Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.

Check it at the source: SEC EDGAR quarterly reports.

Institutional holdings: Many funds opening a new position became public on 14 Nov 2025

Abbvie saw 228 13F filers open a new position in the quarter ended 30 Sep 2025, 1.3× the same quarter last year.

This period
228 (the quarter ended 30 Sep 2025)
Normal quarter (median of 8 earlier)
118
Typical spread (median absolute deviation)
17
How far from its usual level
+4.4
Same quarter last year
172
History used
4,383 days
2023-09-30: 1202023-12-31: 1152024-03-31: 1382024-06-30: 1022024-09-30: 1722024-12-31: 992025-03-31: 1962025-06-30: 1112025-09-30: 228
the quarter ended 30 Sep 20258 earlier quartersnormal: 118

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

Check it at the source: SEC Form 13F data sets.

Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

17 Sep 2024confirmed

Confirmed across sources Hiring and Short interest and volume

Abbvie (ABBV): had 20.2M shares sold short in the 15 Aug 2024 report, 1.5× the same report last year, while it had 45 H-1B/E-3 visa applications certified in May 2024, 3.2× the same month last year. Two unrelated kinds of activity within 21 days.

  • Short interest and volume: Short interest spike, became public on 27 Aug 2024
  • Hiring: H-1B/E-3 applications change, became public on 13 Sep 2024
2023-08-15: 13.3M2023-08-31: 12.5M2023-09-15: 11.9M2023-09-29: 12.3M2023-10-13: 11.5M2023-10-31: 13.2M2023-11-15: 11.1M2023-11-30: 11.1M2023-12-15: 13.7M2023-12-29: 12.1M2024-01-12: 13.6M2024-01-31: 13.7M2024-02-15: 14.7M2024-02-29: 14.3M2024-03-15: 14.7M2024-03-28: 13.1M2024-04-15: 13.5M2024-04-30: 14.5M2024-05-15: 15.9M2024-05-31: 16.5M2024-06-14: 15.2M2024-06-28: 16.2M2024-07-15: 16.4M2024-07-31: 17.5M2024-08-15: 20.2M
The 15 Aug 2024 report against the 24 reports before it. this reportearliernormal: 13.6M
See the evidence (2 changes)

Short interest and volume: Short interest spike became public on 27 Aug 2024

Abbvie had 20.2M shares sold short in the 15 Aug 2024 report, 1.5× the same report last year.

This period
20.2M (the 15 Aug 2024 report)
Normal report (median of 24 earlier)
13.6M
Typical spread (median absolute deviation)
1.2M
How far from its usual level
+3.6
Same report last year
13.3M
History used
2,421 days
2023-08-15: 13.3M2023-08-31: 12.5M2023-09-15: 11.9M2023-09-29: 12.3M2023-10-13: 11.5M2023-10-31: 13.2M2023-11-15: 11.1M2023-11-30: 11.1M2023-12-15: 13.7M2023-12-29: 12.1M2024-01-12: 13.6M2024-01-31: 13.7M2024-02-15: 14.7M2024-02-29: 14.3M2024-03-15: 14.7M2024-03-28: 13.1M2024-04-15: 13.5M2024-04-30: 14.5M2024-05-15: 15.9M2024-05-31: 16.5M2024-06-14: 15.2M2024-06-28: 16.2M2024-07-15: 16.4M2024-07-31: 17.5M2024-08-15: 20.2M
the 15 Aug 2024 report24 earlier reportsnormal: 13.6M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Hiring: H-1B/E-3 applications change became public on 13 Sep 2024

Abbvie had 45 H-1B/E-3 visa applications certified in May 2024, 3.2× the same month last year.

This period
45 (May 2024)
Normal month (median of 4 earlier)
15
Typical spread (median absolute deviation)
1
How far from its usual level
+10.0
Same month last year
14
History used
1,704 days
2020-05-01: 142021-05-01: 162022-05-01: 572023-05-01: 142024-05-01: 45
May 20244 earlier monthsnormal: 15

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 9+ earlier periods, 365+ days of history and a value of at least 20.

Check it at the source: DOL foreign labor disclosure data.

Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

Timeline

Changes and notable records, by the date each became public

  1. 2 Nov 2026Filings record

    Director or officer change

  2. 20 Oct 2026Lobbying record

    TIBER CREEK GROUP OBO ABBVIE INC.: new lobbying registration (B HALL STRATEGIES, LLC) (dated 1 Sep 2026)

  3. 15 Oct 2026Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  4. 15 Oct 2026Filings record

    Director or officer change

  5. 12 Aug 2026Institutional holdings record

    GQG Partners LLC opened a $484.0M position (2026Q2 13F)

  6. 21 Apr 2026several at once

    drew 7,134 Wikipedia page views in the week of 30 Mar 2026, 1.8× the same week last year, while it lobbying on a new issue. Two unrelated kinds of activity within 13 days.

    See the evidence (2 changes)

    Attention: Wikipedia attention spike became public on 7 Apr 2026

    Abbvie drew 7,134 Wikipedia page views in the week of 30 Mar 2026, 1.8× the same week last year.

    This period
    7,134 (the week of 30 Mar 2026)
    Normal week (median of 26 earlier)
    3,559
    Typical spread (median absolute deviation)
    193
    How far from its usual level
    +10.0
    Same week last year
    3,941
    History used
    2,651 days
    2025-09-29: 4,4652025-10-06: 3,7172025-10-13: 3,4882025-10-20: 3,3742025-10-27: 3,4562025-11-03: 3,3582025-11-10: 3,5672025-11-17: 3,6032025-11-24: 3,5292025-12-01: 3,7722025-12-08: 3,6482025-12-15: 3,6682025-12-22: 2,5112025-12-29: 2,5422026-01-05: 3,8892026-01-12: 4,3412026-01-19: 4,1022026-01-26: 4,1732026-02-02: 4,1902026-02-09: 3,5022026-02-16: 3,3522026-02-23: 3,5812026-03-02: 3,3142026-03-09: 3,2742026-03-16: 3,4462026-03-23: 3,5512026-03-30: 7,134
    the week of 30 Mar 202626 earlier weeksnormal: 3,559

    Fires when the period is at least 5.0 robust standard deviations above the company's own median, with 20+ earlier periods, 365+ days of history and a value of at least 5,000.

    Check it at the source: Wikimedia page view statistics.

    Lobbying: Lobbying on a new issue became public on 21 Apr 2026

    Abbvie lobbying on a new issue.

    New
    ['CSP']
    Rule
    only points whose every posting (and value revision) is at or before as_of
    Field
    issue_codes
    Metric
    lobbying.filings_count
    Point id
    4685366

    Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

  7. 21 Apr 2026Lobbying change

    lobbying on a new issue.

    See the evidence
    New
    ['CSP']
    Rule
    only points whose every posting (and value revision) is at or before as_of
    Field
    issue_codes
    Metric
    lobbying.filings_count
    Point id
    4685366
  8. 7 Apr 2026Attention change

    drew 7,134 Wikipedia page views in the week of 30 Mar 2026, 1.8× the same week last year.

    Same week last year: 3,941; its normal week is 3,559.

    See the evidence
    This period
    7,134 (the week of 30 Mar 2026)
    Normal week (median of 26 earlier)
    3,559
    Typical spread (median absolute deviation)
    193
    How far from its usual level
    +10.0
    Same week last year
    3,941
    History used
    2,651 days
    2025-09-29: 4,4652025-10-06: 3,7172025-10-13: 3,4882025-10-20: 3,3742025-10-27: 3,4562025-11-03: 3,3582025-11-10: 3,5672025-11-17: 3,6032025-11-24: 3,5292025-12-01: 3,7722025-12-08: 3,6482025-12-15: 3,6682025-12-22: 2,5112025-12-29: 2,5422026-01-05: 3,8892026-01-12: 4,3412026-01-19: 4,1022026-01-26: 4,1732026-02-02: 4,1902026-02-09: 3,5022026-02-16: 3,3522026-02-23: 3,5812026-03-02: 3,3142026-03-09: 3,2742026-03-16: 3,4462026-03-23: 3,5512026-03-30: 7,134
    the week of 30 Mar 202626 earlier weeksnormal: 3,559

    Fires when the period is at least 5.0 robust standard deviations above the company's own median, with 20+ earlier periods, 365+ days of history and a value of at least 5,000.

    Check it at the source: Wikimedia page view statistics.

  9. 20 Mar 2026Lobbying record

    ABBVIE, INC.: new lobbying registration (WILLIAMS AND JENSEN, PLLC)

  10. 11 Feb 2026Lobbying record

    ABBVIE INC.: new lobbying registration (CHECKMATE GOVERNMENT RELATIONS) (dated 21 Jan 2026)

  11. 18 Nov 2025several at once

    spent $381.0M on capital projects in the quarter ended 30 Sep 2025, 1.5× the same quarter last year, while it saw 228 13F filers open a new position in the quarter ended 30 Sep 2025, 1.3× the same quarter last year. Two unrelated kinds of activity within 12 days.

    See the evidence (2 changes)

    Financials: Quarterly capital spending jump became public on 6 Nov 2025

    Abbvie spent $381.0M on capital projects in the quarter ended 30 Sep 2025, 1.5× the same quarter last year.

    This period
    $381.0M (the quarter ended 30 Sep 2025)
    Normal quarter (median of 8 earlier)
    $238.0M
    Typical spread (median absolute deviation)
    $25.0M
    How far from its usual level
    +3.9
    Same quarter last year
    $249.0M
    History used
    3,470 days
    2023-09-30: $219.0M2023-12-31: $205.0M2024-03-31: $193.0M2024-06-30: $241.0M2024-09-30: $249.0M2024-12-31: $291.0M2025-03-31: $235.0M2025-06-30: $269.0M2025-09-30: $381.0M
    the quarter ended 30 Sep 20258 earlier quartersnormal: $238.0M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.

    Check it at the source: SEC EDGAR quarterly reports.

    Institutional holdings: Many funds opening a new position became public on 14 Nov 2025

    Abbvie saw 228 13F filers open a new position in the quarter ended 30 Sep 2025, 1.3× the same quarter last year.

    This period
    228 (the quarter ended 30 Sep 2025)
    Normal quarter (median of 8 earlier)
    118
    Typical spread (median absolute deviation)
    17
    How far from its usual level
    +4.4
    Same quarter last year
    172
    History used
    4,383 days
    2023-09-30: 1202023-12-31: 1152024-03-31: 1382024-06-30: 1022024-09-30: 1722024-12-31: 992025-03-31: 1962025-06-30: 1112025-09-30: 228
    the quarter ended 30 Sep 20258 earlier quartersnormal: 118

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

    Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

  12. 14 Nov 2025Institutional holdings change

    saw 228 13F filers open a new position in the quarter ended 30 Sep 2025, 1.3× the same quarter last year.

    Same quarter last year: 172; its normal quarter is 118.

    See the evidence
    This period
    228 (the quarter ended 30 Sep 2025)
    Normal quarter (median of 8 earlier)
    118
    Typical spread (median absolute deviation)
    17
    How far from its usual level
    +4.4
    Same quarter last year
    172
    History used
    4,383 days
    2023-09-30: 1202023-12-31: 1152024-03-31: 1382024-06-30: 1022024-09-30: 1722024-12-31: 992025-03-31: 1962025-06-30: 1112025-09-30: 228
    the quarter ended 30 Sep 20258 earlier quartersnormal: 118

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

  13. 6 Nov 2025Financials change

    spent $381.0M on capital projects in the quarter ended 30 Sep 2025, 1.5× the same quarter last year.

    Same quarter last year: $249.0M; its normal quarter is $238.0M.

    See the evidence
    This period
    $381.0M (the quarter ended 30 Sep 2025)
    Normal quarter (median of 8 earlier)
    $238.0M
    Typical spread (median absolute deviation)
    $25.0M
    How far from its usual level
    +3.9
    Same quarter last year
    $249.0M
    History used
    3,470 days
    2023-09-30: $219.0M2023-12-31: $205.0M2024-03-31: $193.0M2024-06-30: $241.0M2024-09-30: $249.0M2024-12-31: $291.0M2025-03-31: $235.0M2025-06-30: $269.0M2025-09-30: $381.0M
    the quarter ended 30 Sep 20258 earlier quartersnormal: $238.0M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  14. 22 Jul 2025Lobbying change

    lobbying on a new issue.

    See the evidence
    New
    ['TAR']
    Rule
    only points whose every posting (and value revision) is at or before as_of
    Field
    issue_codes
    Metric
    lobbying.filings_count
    Point id
    4821536
  15. 21 Jul 2025Lobbying record

    ABBVIE: new lobbying registration (ACG ADVOCACY) (dated 1 May 2025)

  16. 15 May 2025Institutional holdings change

    saw 196 13F filers open a new position in the quarter ended 31 Mar 2025, 1.4× the same quarter last year.

    Same quarter last year: 138; its normal quarter is 108.

    See the evidence
    This period
    196 (the quarter ended 31 Mar 2025)
    Normal quarter (median of 8 earlier)
    108
    Typical spread (median absolute deviation)
    13
    How far from its usual level
    +4.5
    Same quarter last year
    138
    History used
    4,200 days
    2023-03-31: 922023-06-30: 942023-09-30: 1202023-12-31: 1152024-03-31: 1382024-06-30: 1022024-09-30: 1722024-12-31: 992025-03-31: 196
    the quarter ended 31 Mar 20258 earlier quartersnormal: 108

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

  17. 12 May 2025Filings record

    Director or officer change

  18. 14 Feb 2025Filings record

    Director or officer change

  19. 10 Jan 2025Filings record

    Asset write-down (impairment)

  20. 13 Dec 2024Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  21. 13 Dec 2024Filings record

    Director or officer change

  22. 17 Sep 2024several at once

    had 20.2M shares sold short in the 15 Aug 2024 report, 1.5× the same report last year, while it had 45 H-1B/E-3 visa applications certified in May 2024, 3.2× the same month last year. Two unrelated kinds of activity within 21 days.

    See the evidence (2 changes)

    Short interest and volume: Short interest spike became public on 27 Aug 2024

    Abbvie had 20.2M shares sold short in the 15 Aug 2024 report, 1.5× the same report last year.

    This period
    20.2M (the 15 Aug 2024 report)
    Normal report (median of 24 earlier)
    13.6M
    Typical spread (median absolute deviation)
    1.2M
    How far from its usual level
    +3.6
    Same report last year
    13.3M
    History used
    2,421 days
    2023-08-15: 13.3M2023-08-31: 12.5M2023-09-15: 11.9M2023-09-29: 12.3M2023-10-13: 11.5M2023-10-31: 13.2M2023-11-15: 11.1M2023-11-30: 11.1M2023-12-15: 13.7M2023-12-29: 12.1M2024-01-12: 13.6M2024-01-31: 13.7M2024-02-15: 14.7M2024-02-29: 14.3M2024-03-15: 14.7M2024-03-28: 13.1M2024-04-15: 13.5M2024-04-30: 14.5M2024-05-15: 15.9M2024-05-31: 16.5M2024-06-14: 15.2M2024-06-28: 16.2M2024-07-15: 16.4M2024-07-31: 17.5M2024-08-15: 20.2M
    the 15 Aug 2024 report24 earlier reportsnormal: 13.6M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Hiring: H-1B/E-3 applications change became public on 13 Sep 2024

    Abbvie had 45 H-1B/E-3 visa applications certified in May 2024, 3.2× the same month last year.

    This period
    45 (May 2024)
    Normal month (median of 4 earlier)
    15
    Typical spread (median absolute deviation)
    1
    How far from its usual level
    +10.0
    Same month last year
    14
    History used
    1,704 days
    2020-05-01: 142021-05-01: 162022-05-01: 572023-05-01: 142024-05-01: 45
    May 20244 earlier monthsnormal: 15

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 9+ earlier periods, 365+ days of history and a value of at least 20.

    Check it at the source: DOL foreign labor disclosure data.

    Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

  23. 13 Sep 2024Hiring change

    had 45 H-1B/E-3 visa applications certified in May 2024, 3.2× the same month last year.

    Same month last year: 14; its normal month is 15.

    See the evidence
    This period
    45 (May 2024)
    Normal month (median of 4 earlier)
    15
    Typical spread (median absolute deviation)
    1
    How far from its usual level
    +10.0
    Same month last year
    14
    History used
    1,704 days
    2020-05-01: 142021-05-01: 162022-05-01: 572023-05-01: 142024-05-01: 45
    May 20244 earlier monthsnormal: 15

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 9+ earlier periods, 365+ days of history and a value of at least 20.

    Check it at the source: DOL foreign labor disclosure data.

  24. 27 Aug 2024Short interest and volume change

    had 20.2M shares sold short in the 15 Aug 2024 report, 1.5× the same report last year.

    Same report last year: 13.3M; its normal report is 13.6M.

    See the evidence
    This period
    20.2M (the 15 Aug 2024 report)
    Normal report (median of 24 earlier)
    13.6M
    Typical spread (median absolute deviation)
    1.2M
    How far from its usual level
    +3.6
    Same report last year
    13.3M
    History used
    2,421 days
    2023-08-15: 13.3M2023-08-31: 12.5M2023-09-15: 11.9M2023-09-29: 12.3M2023-10-13: 11.5M2023-10-31: 13.2M2023-11-15: 11.1M2023-11-30: 11.1M2023-12-15: 13.7M2023-12-29: 12.1M2024-01-12: 13.6M2024-01-31: 13.7M2024-02-15: 14.7M2024-02-29: 14.3M2024-03-15: 14.7M2024-03-28: 13.1M2024-04-15: 13.5M2024-04-30: 14.5M2024-05-15: 15.9M2024-05-31: 16.5M2024-06-14: 15.2M2024-06-28: 16.2M2024-07-15: 16.4M2024-07-31: 17.5M2024-08-15: 20.2M
    the 15 Aug 2024 report24 earlier reportsnormal: 13.6M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  25. 23 Apr 2024Lobbying change

    lobbying on a new issue.

    See the evidence
    New
    ['LBR']
    Rule
    only points whose every posting (and value revision) is at or before as_of
    Field
    issue_codes
    Metric
    lobbying.filings_count
    Point id
    6540005
  26. 20 Feb 2024Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  27. 20 Feb 2024Filings record

    Director or officer change

  28. 14 Feb 2024Institutional holdings record

    Holocene Advisors, LP opened a $257.0M position (2023Q4 13F)

  29. 12 Oct 2023Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  30. 12 Oct 2023Filings record

    Director or officer change

  31. 11 Sep 2023Lobbying record

    ABBVIE INC.: new lobbying registration (MARSHALL & POPP, LLC) (dated 6 Sep 2023)

  32. 29 Jun 2023Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  33. 29 Jun 2023Filings record

    Director or officer change

  34. 31 Jan 2023Attention change

    drew 5,621 Wikipedia page views in the week of 23 Jan 2023, 1.5× the same week last year.

    Same week last year: 3,792; its normal week is 3,344.

    See the evidence
    This period
    5,621 (the week of 23 Jan 2023)
    Normal week (median of 26 earlier)
    3,344
    Typical spread (median absolute deviation)
    123
    How far from its usual level
    +6.8
    Same week last year
    3,792
    History used
    1,489 days
    2022-07-25: 3,5212022-08-01: 3,3672022-08-08: 3,2222022-08-15: 3,2202022-08-22: 3,3022022-08-29: 3,0762022-09-05: 3,1742022-09-12: 3,4132022-09-19: 3,4272022-09-26: 3,3872022-10-03: 3,6432022-10-10: 3,4232022-10-17: 3,3392022-10-24: 3,3442022-10-31: 3,4632022-11-07: 3,3622022-11-14: 3,3442022-11-21: 2,9012022-11-28: 3,3122022-12-05: 3,1692022-12-12: 3,1192022-12-19: 2,7252022-12-26: 2,5832023-01-02: 3,6042023-01-09: 3,8672023-01-16: 3,8902023-01-23: 5,621
    the week of 23 Jan 202326 earlier weeksnormal: 3,344

    Fires when the period is at least 5.0 robust standard deviations above the company's own median, with 20+ earlier periods, 365+ days of history and a value of at least 5,000.

    Check it at the source: Wikimedia page view statistics.

  35. 20 Jan 2023Lobbying record

    ABBVIE INC.: lobbying engagement terminated (OGR) (dated 31 Dec 2022)

  36. 29 Nov 2022Filings record

    Director or officer change

  37. 17 Oct 2022Filings record

    Director or officer change

  38. 14 Oct 2022Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  39. 14 Oct 2022Filings record

    Director or officer change

  40. 28 Sep 2022Hiring change

    had 57 H-1B/E-3 visa applications certified in May 2022, 3.6× the same month last year.

    Same month last year: 16; its normal month is 15.

    See the evidence
    This period
    57 (May 2022)
    Normal month (median of 2 earlier)
    15
    Typical spread (median absolute deviation)
    1
    How far from its usual level
    +14.0
    Same month last year
    16
    History used
    973 days
    2020-05-01: 142021-05-01: 162022-05-01: 57
    May 20222 earlier monthsnormal: 15

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 9+ earlier periods, 365+ days of history and a value of at least 20.

    Check it at the source: DOL foreign labor disclosure data.

Showing the newest 40 of 133 entries; narrow the window or the kind of data to see older ones.

Not listed: 299 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.

Articles about this company

The latest 1 that name ABBV

Identifiers and sources

How records are matched to this company, and what each source holds for it

Cik
0001551152
Ticker
ABBV
Domain
abbvie.com
Employer name
ABBVIE INC., ABBVIE US LLC (2 unverified)
Hq location
IL|NORTH CHICAGO|60064 (1 unverified)
Lobbying client
abbvie, peck madigan jones on behalf of abbvie, tiber creek group obo abbvie
Name
abbv-20251231xex21, abbv-20251231xex21.htm, AbbVie Finance Corporation Delaware, ABBVIE INC. and 27 more
Uei
VAFXUGJBLML4
Wikidata
Q14662364
Wikipedia
AbbVie
  • DOL H-1B labor condition applications and PERM certifications1865 data points1 Oct 2019 to 28 Sep 2026
  • Federal lobbying disclosures (LDA)29 records, 165 data points1 Feb 2013 to 30 Sep 2026
  • SEC Form 13F institutional holdings12 records, 481 data points30 Jun 2013 to 30 Sep 2026
  • SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)187 records29 Jan 2016 to 3 Nov 2026
  • SEC XBRL company facts (revenue, capex, R&D, backlog...)1000 data points31 Dec 2010 to 26 Oct 2026
  • SEC Form 4 insider transactions160 records, 428 data points2 Mar 2016 to 12 Nov 2026
  • FINRA short interest (twice monthly)636 data points29 Dec 2017 to 30 Oct 2026
  • FINRA daily short sale volume (off-exchange)4178 data points1 Aug 2018 to 20 Nov 2026
  • USASpending.gov federal awards1364 data points16 Dec 2014 to 9 Sep 2026
  • WARN layoff notices (state labor agencies)4 records, 9 data points28 May 2012 to 1 Jul 2021
  • Wikipedia pageviews2882 data points1 Jan 2019 to 21 Nov 2026